Jetema (216080.KQ), an aesthetics specialist, has obtained final product approval for its botulinum toxin from the Thai Food and Drug Administration (TFDA).
Jetema announced Wednesday that it had received final product approval from the Thai Food and Drug Administration for its botulinum toxin "Jetema The Toxin 100U." It marks the company's first botulinum toxin approval overseas.
The company expects the approval to go beyond a simple licensing milestone and drive actual earnings. Jetema's local partner, Aestema, is a medical aesthetics distributor that ranks first in sales of Korean-made fillers in Thailand.
Based on the strong local sales network and brand recognition built by Aestema, Jetema will begin its first large-scale shipment next month. Through this, an already-signed five-year supply contract worth 32 million dollars (44 billion won) will translate into confirmed revenue, and along with the inflow of remaining milestones (stage-based technology fees), the company expects a sharp increase in earnings in the second half.
"This Thai product approval is the first overseas botulinum toxin approval the company has achieved, and it is a symbolic accomplishment marking the 'first year of global expansion' as we leap into a true global aesthetics company," a Jetema official said.
